Company: GMRE
Filing Date: 2025-11-14
Form Type: 424B5
Source: 0001104659-25-112543
Chunk: 47

Company: Global Medical REIT Inc.
Filing Date: 2025-11-14
Form: 424B5
Chunk 47
---
 Series B
Preferred Stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of
applicable securities laws.

Securities legislation in certain provinces or
territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto)
contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable
provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with
a legal advisor.

Pursuant to section 3A.3 of National Instrument
33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding
underwriter conflicts of interest in connection with this offering.

Prohibition of Sales to European Economic Area Retail Investors

The shares of Series B Preferred Stock are
not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail
investor in the European Economic Area (“EEA”). For these purposes, a retail investor means a person who is one (or more)
of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MiFID II”);
(ii) a customer within the meaning of Directive 2016/97/EU (as amended, the “Insurance Distribution Directive”), where
that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not
a qualified investor as defined in Regulation (EU) 2017/1129 (the “Prospectus Regulation”). Consequently, no key information
document required by Regulation (EU) No 1286/2014 (as amended, the “PRIIPs Regulation”) for offering or selling the shares
of Series B Preferred Stock or otherwise making them available to retail investors in the EEA has been prepared and therefore offering
or selling shares of Series B Preferred Stock or otherwise making them available to any retail investor in the EEA may be unlawful
under the PRIIPs Regulation.

Prohibition of Sales to United Kingdom Retail Investors

The shares of Series B